MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10096-026-05702-2

Медицинская библиотека · European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026

Desensitisation protocol for ethambutol in the treatment of Mycobacterium avium complex pulmonary disease.

Denby George, Holt Michael, Wilson Malcolm, Grey Victoria, Burke Andrew, Thomson Rachel, Evans Ieuan Edward Shepherd

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Ethambutol is a key component of treatment for Mycobacterium avium complex pulmonary disease (MAC-PD), primarily through suppression of macrolide resistance. However, adverse drug reactions frequently lead to treatment interruption, and evidence-based alternatives remain limited. We evaluated the feasibility and outcomes of a structured outpatient ethambutol desensitisation protocol in patients with MAC-PD who developed ethambutol intolerance or hypersensitivity.

METHODS

We conducted a multicentre observational study across four specialist NTM centres. Patients undergoing treatment for MAC-PD who experienced an ethambutol-related adverse reaction leading to drug cessation were eligible. A patient-led outpatient desensitisation protocol commenced at 25 mg daily with gradual dose escalation to a weight-based target dose. The protocol allowed temporary dose reduction to previously tolerated levels if symptoms recurred. Success was defined as achievement of the target dose or maintenance of a tolerated dose associated with sustained culture conversion.

RESULTS

Twenty desensitisation episodes were performed in 17 patients (65% female; mean age 72 years). The most common indication was rash (70%), followed by headache (15%). Overall, 17/20 (85%) desensitisations were successful, including 13/14 (93%) among patients with delayed cutaneous reactions. Mean time to target dose was 9 weeks (median 4 weeks). No severe immediate hypersensitivity reactions occurred during desensitisation. Sixteen episodes (80%) were associated with culture conversion, and 11 (55%) patients completed therapy with ethambutol-containing regimens.

CONCLUSIONS

Outpatient ethambutol desensitisation appears feasible, safe and effective in selected patients with MAC-PD and non-severe ethambutol intolerance. This approach may help preserve an essential component of MAC therapy when treatment options are otherwise limited.

Для цитирования: Denby George, Holt Michael, Wilson Malcolm, Grey Victoria, Burke Andrew, Thomson Rachel, Evans Ieuan Edward Shepherd. Desensitisation protocol for ethambutol in the treatment of Mycobacterium avium complex pulmonary disease.. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2026. DOI: 10.1007/s10096-026-05702-2.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.